Fluphenazine

Dosage for Fluphenazine must be highly individualized, as the optimal therapeutic dose varies significantly between patients. Healthcare providers typically aim for the lowest effective dose to minimize the risk of neurological side effects.

• For Schizophrenia (Oral Hydrochloride): The initial adult dose usually ranges from 2.5 mg to 10 mg per day, divided into doses given every 6 to 8 hours. As the patient stabilizes, the dose may be increased. Most patients are maintained on a total daily dose of 1.0 mg to 5.0 mg, often administered as a single daily dose. Doses above 20 mg per day should be used with extreme caution, and the absolute maximum is generally considered 40 mg per day in highly resistant cases.
• Acute Agitation (IM Hydrochloride): For rapid onset, an initial dose of 1.25 mg to 2.5 mg may be administered intramuscularly. Subsequent doses are adjusted based on the patient's response.

Fluphenazine is generally not recommended for use in children under the age of 12. For adolescents over 12, healthcare providers may occasionally prescribe low doses if other first-line treatments are ineffective. However, because of the high risk of extrapyramidal side effects (involuntary movements) in younger populations, extreme caution is required. Pediatric dosing, when used, usually begins at the lowest possible range (e.g., 0.25 mg to 0.5 mg daily) and is titrated very slowly under the close supervision of a child psychiatrist.

Renal Impairment

While Fluphenazine is primarily metabolized by the liver, its metabolites are excreted by the kidneys. In patients with significant renal (kidney) impairment, the clearance of these metabolites may be reduced. Doctors may choose to start at the lower end of the dosing spectrum and monitor kidney function tests (BUN and Creatinine) regularly.

Hepatic Impairment

Because the liver is the primary site of Fluphenazine metabolism, patients with hepatic (liver) disease are at a significantly higher risk of drug accumulation and toxicity. Lower initial doses and slower titration are mandatory. If liver enzymes (ALT/AST) become significantly elevated during treatment, the medication may need to be discontinued.

Elderly Patients

Geriatric patients are particularly sensitive to the effects of Fluphenazine. They are at a much higher risk for orthostatic hypotension (a sudden drop in blood pressure when standing) and tardive dyskinesia. Healthcare providers typically start elderly patients on 1 mg to 2.5 mg daily and increase the dose very gradually.

• Consistency: Take Fluphenazine at the same time(s) each day to maintain stable blood levels.
• Food: The tablets can be taken with or without food. If the medication causes stomach upset, taking it with a meal or a glass of milk may help.
• Liquid Form: If using the oral solution, use the provided calibrated dropper to ensure an accurate dose. The solution can be mixed with water, milk, or fruit juice (avoid caffeinated beverages or apple juice as they may affect absorption).
• Storage: Store the medication at room temperature (68°F to 77°F), away from moisture and direct light. The liquid and injectable forms are particularly sensitive to light and should be kept in their original amber containers.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to "make up" for a missed one, as this increases the risk of acute side effects.

An overdose of Fluphenazine is a medical emergency. Symptoms may include severe extrapyramidal reactions (muscle rigidity, tremors), extreme sedation, low blood pressure (hypotension), and potentially life-threatening heart rhythm disturbances. If an overdose is suspected, contact a poison control center or emergency services immediately. Treatment is primarily supportive and may involve gastric lavage (stomach pumping) and the administration of intravenous fluids or medications to counteract muscle rigidity.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Abruptly stopping the medication can lead to a return of psychotic symptoms or withdrawal-like effects.

Because Fluphenazine is a high-potency dopamine blocker, side effects related to the nervous system are very common.

• Extrapyramidal Symptoms (EPS): These are the most frequent side effects. They include pseudoparkinsonism (tremors, shuffling gait, muscle stiffness), akathisia (a distressing feeling of inner restlessness and the need to move), and acute dystonia (sudden, painful muscle contractions, often in the neck or face).
• Drowsiness: Many patients experience significant sedation, especially during the first few weeks of treatment.
• Dry Mouth: Reduced salivation can lead to discomfort and increased risk of dental cavities.
• Blurred Vision: Difficulty focusing the eyes is common as the drug affects the autonomic nervous system.

• Weight Gain: While less pronounced than with newer antipsychotics, some patients may experience changes in appetite and weight.
• Constipation: Slowed gastrointestinal motility is a known side effect of phenothiazines.
• Nausea and Vomiting: Some patients may experience initial digestive upset.
• Orthostatic Hypotension: A feeling of dizziness or lightheadedness when standing up quickly due to a temporary drop in blood pressure.
• Hyperprolactinemia: Fluphenazine can increase levels of the hormone prolactin, which may lead to breast swelling (gynecomastia in men), nipple discharge (galactorrhea), or menstrual irregularities in women.

• Agranulocytosis: A dangerous drop in white blood cell counts that leaves the body vulnerable to infection.
• Cholestatic Jaundice: A liver condition characterized by yellowing of the skin and eyes, upper abdominal pain, and dark urine.
• Photosensitivity: Increased sensitivity to sunlight, resulting in severe sunburns even with minimal exposure.
• Seizures: Fluphenazine can lower the seizure threshold, especially in patients with a history of epilepsy.

> Warning: Stop taking Fluphenazine and call your doctor immediately if you experience any of these.

• Neuroleptic Malignant Syndrome (NMS): This is a rare but potentially fatal reaction. Symptoms include high fever, severe muscle rigidity, confusion, fast or irregular heartbeat, and heavy sweating.
• Tardive Dyskinesia (TD): This condition involves involuntary, repetitive body movements, such as grimacing, sticking out the tongue, or smacking the lips. TD can become permanent if the medication is not adjusted or stopped.
• Severe Allergic Reaction: Symptoms include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.
• Priapism: A painful, prolonged erection that lasts for 4 hours or more, which requires emergency urological intervention.
• Heatstroke: Fluphenazine interferes with the body's ability to regulate temperature; avoid extreme heat and stay hydrated.

With prolonged use, the risk of developing Tardive Dyskinesia increases significantly. The risk is highest in elderly patients, particularly women. Additionally, long-term use of typical antipsychotics has been associated with "post-psychotic depression" in some individuals. Regular monitoring via the Abnormal Involuntary Movement Scale (AIMS) is recommended every 3 to 6 months for patients on chronic Fluphenazine therapy.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: The FDA has issued a black box warning for all antipsychotics, including Fluphenazine. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death, primarily due to cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) causes. Fluphenazine is not approved for the treatment of patients with dementia-related psychosis.

Report any unusual symptoms to your healthcare provider. Early detection of side effects is crucial for adjusting the treatment plan safely.

Fluphenazine is a powerful medication that requires careful medical supervision. Patients should be aware that this drug can impair the mental and physical abilities required for driving or operating heavy machinery. This effect is most pronounced during the first few days of treatment or following a dose increase. Additionally, Fluphenazine can affect the body's ability to cool itself down, making patients more susceptible to heatstroke during hot weather or vigorous exercise.

Elderly Patients with Dementia-Related Psychosis: Clinical trials have shown that elderly patients with dementia-related psychosis who are treated with antipsychotic medications face a significantly higher risk of death compared to those receiving a placebo. Most deaths were related to heart problems or infections like pneumonia. Fluphenazine is strictly not indicated for the treatment of psychosis associated with dementia.

• Neuroleptic Malignant Syndrome (NMS): This is a life-threatening neurological emergency associated with the use of antipsychotic agents. If a patient develops a high fever, "lead-pipe" muscle rigidity, or altered mental status, the drug must be discontinued immediately, and intensive symptomatic treatment must be initiated.
• Tardive Dyskinesia (TD): Because the risk of developing TD increases with the duration of treatment and the total cumulative dose, Fluphenazine should be prescribed in a manner that minimizes this risk. If signs of TD appear, discontinuation of the drug should be considered.
• QT Prolongation: Like many phenothiazines, Fluphenazine can affect the electrical activity of the heart, potentially leading to a dangerous heart rhythm known as Torsades de Pointes. This risk is higher if the drug is taken with other medications that also prolong the QT interval.
• Leukopenia, Neutropenia, and Agranulocytosis: Patients with a history of low white blood cell counts should have their blood monitored frequently during the first few months of therapy.

Patients taking Fluphenazine require regular clinical monitoring to ensure safety:

• AIMS Testing: The Abnormal Involuntary Movement Scale (AIMS) should be used periodically to check for signs of Tardive Dyskinesia.
• Blood Counts: A Complete Blood Count (CBC) is often performed to monitor for agranulocytosis.
• Liver Function: Periodic liver enzyme tests (ALT, AST, Bilirubin) are recommended, especially if the patient develops signs of jaundice.
• Blood Pressure: Regular monitoring for orthostatic hypotension is necessary, particularly in the elderly.

Do not drive, operate heavy machinery, or engage in hazardous activities until you know how Fluphenazine affects you. The sedative effects and potential for blurred vision can significantly impair your reaction time and coordination.

Alcohol must be strictly avoided while taking Fluphenazine. Alcohol increases the central nervous system (CNS) depressant effects of the medication, leading to extreme drowsiness, respiratory depression, and an increased risk of accidental injury or overdose.

Never stop taking Fluphenazine suddenly. Abrupt discontinuation can lead to "withdrawal emergent neurological signs" or a rapid return of psychotic symptoms. If the medication needs to be stopped, your healthcare provider will provide a tapering schedule to slowly reduce the dose over several weeks.

> Important: Discuss all your medical conditions with your healthcare provider before starting Fluphenazine, especially if you have a history of liver disease, kidney disease, seizures, or heart problems.

Certain medications should never be used in combination with Fluphenazine due to the risk of life-threatening complications:

• CNS Depressants in High Doses: Combining Fluphenazine with high doses of barbiturates or other potent sedatives can lead to fatal respiratory depression.
• Drugs that Severely Prolong QT Interval: Medications like thioridazine or certain antiarrhythmics (e.g., sotalol) should be avoided to prevent fatal cardiac arrhythmias.
• Bone Marrow Suppressants: Drugs known to cause agranulocytosis (e.g., clozapine) should not be used concurrently as they compound the risk of severe immune system suppression.

• Anticholinergic Drugs: Medications for overactive bladder or Parkinson's (e.g., benztropine, atropine) can increase the risk of heatstroke, severe constipation, and paralytic ileus when combined with Fluphenazine.
• Lithium: There have been rare reports of an encephalopathic syndrome (brain dysfunction) in patients taking both lithium and a phenothiazine. Symptoms include weakness, fever, and tremors. Monitor for neurological changes closely.
• Antihypertensives: Fluphenazine can enhance the effects of blood pressure medications, leading to severe hypotension (low blood pressure).

• Dopamine Agonists: Fluphenazine blocks dopamine receptors, which directly opposes the action of drugs used for Parkinson’s disease, such as Levodopa. This can result in a loss of symptom control for Parkinson's patients.
• CYP2D6 Inhibitors: Drugs like fluoxetine, paroxetine, and quinidine inhibit the enzyme that breaks down Fluphenazine. This can lead to toxic levels of Fluphenazine in the blood.
• Anticonvulsants: Fluphenazine may lower the seizure threshold, requiring an adjustment in the dose of anti-seizure medications like phenytoin or carbamazepine.

• Alcohol: As noted, alcohol significantly increases sedation and the risk of respiratory distress.
• Caffeine: High intake of caffeine may reduce the effectiveness of Fluphenazine by stimulating the nervous system and potentially interfering with the drug's absorption in the gut.
• Grapefruit: While not as significantly impacted as other drugs, grapefruit can theoretically inhibit certain metabolic pathways, potentially increasing drug levels.

• St. John’s Wort: This herb can induce liver enzymes, potentially leading to faster clearance of Fluphenazine and reduced therapeutic efficacy.
• Kava Kava and Valerian Root: These supplements have sedative properties that can dangerously increase the drowsiness caused by Fluphenazine.
• Evening Primrose Oil: Some studies suggest this may lower the seizure threshold, which, when combined with Fluphenazine, increases the risk of convulsions.

Fluphenazine can cause false-positive results on certain laboratory tests:

• Pregnancy Tests: It may cause false-positive results on urine pregnancy tests.
• Urinary Bilirubin: It can interfere with tests for bilirubin in the urine.
• Metabolic Tests: It may affect the results of protein-bound iodine (PBI) tests and glucose tolerance tests.

For each major interaction, the mechanism usually involves either a pharmacodynamic interaction (where two drugs have opposing or additive effects on the body) or a pharmacokinetic interaction (where one drug changes how the other is absorbed or metabolized). Management typically involves adjusting dosages, choosing alternative medications, or increasing clinical monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous interactions.

Fluphenazine must NEVER be used in the following circumstances:

• Comatose or Severely Depressed States: Because Fluphenazine is a CNS depressant, it can deepen a coma or worsen severe central nervous system depression, potentially leading to death.
• Existing Blood Dyscrasias: Patients with a history of bone marrow suppression or blood disorders (like agranulocytosis) should not take this drug, as it can further lower white blood cell counts.
• Substantial Liver Damage: In the presence of severe hepatic failure, the body cannot metabolize the drug, leading to rapid toxicity.
• Hypersensitivity: A known allergy to Fluphenazine or other phenothiazines (e.g., prochlorperazine, chlorpromazine) is an absolute contraindication due to the risk of anaphylaxis.
• Severe Cardiovascular Disease: Patients with uncompensated heart failure or severe hypotension should avoid this medication as it can exacerbate these conditions.

In these cases, a healthcare provider must perform a careful risk-benefit analysis:

• Seizure Disorders: Because the drug lowers the seizure threshold, it must be used with extreme caution in patients with epilepsy.
• Glaucoma: The mild anticholinergic effects of Fluphenazine can increase intraocular pressure, potentially worsening narrow-angle glaucoma.
• Prostatic Hypertrophy: Men with an enlarged prostate may experience worsening urinary retention.
• Extreme Heat Exposure: Those who work in high-temperature environments are at a significantly higher risk of hyperthermia and heatstroke.

Patients who have had a severe adverse reaction or allergic response to any phenothiazine antipsychotic are highly likely to have a similar reaction to Fluphenazine. This "cross-sensitivity" occurs because these drugs share a similar chemical structure. Always inform your doctor if you have ever had a bad reaction to any "major tranquilizer" or antipsychotic in the past.

> Important: Your healthcare provider will evaluate your complete medical history, including any past reactions to medications, before prescribing Fluphenazine to ensure it is safe for you.

Fluphenazine is classified by the FDA as Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, and there are no adequate and well-controlled studies in humans. However, the potential benefits may warrant use of the drug in pregnant women despite potential risks.

There is a risk of Extrapyramidal Signs (EPS) and withdrawal symptoms in newborns whose mothers took Fluphenazine during the third trimester. These symptoms in the neonate may include agitation, hypertonia (increased muscle tone), hypotonia (decreased muscle tone), tremor, somnolence, and respiratory distress. Use during pregnancy should only occur if the clinical need for treating the mother's psychosis outweighs the risk to the fetus.

Fluphenazine is known to be excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants (such as extreme sedation and movement disorders), a decision should be made whether to discontinue nursing or discontinue the drug. In most cases, if Fluphenazine is essential for the mother's health, healthcare providers recommend alternative feeding methods for the infant.

As previously noted, Fluphenazine is not approved for use in children under 12 years of age. Adolescents may be more susceptible to acute dystonic reactions and other extrapyramidal symptoms. Long-term effects on growth and development have not been extensively studied, making it a second or third-line choice for pediatric psychotic disorders.

Elderly patients require the most caution. They are at the highest risk for:

• Cerebrovascular Adverse Events: Including an increased risk of stroke.
• Falls: Due to sedation and orthostatic hypotension.
• Tardive Dyskinesia: The risk of permanent movement disorders is significantly higher in the elderly.
• Polypharmacy: Elderly patients are often on multiple medications, increasing the risk of complex drug-drug interactions.

While the liver does the heavy lifting for metabolism, the kidneys filter the metabolites. In patients with a Glomerular Filtration Rate (GFR) below 30 mL/min, the dose should be reduced by at least 50%, and the patient should be monitored for signs of increased sedation or neurological side effects. Fluphenazine is not significantly cleared by hemodialysis.

For patients with Child-Pugh Class B or C hepatic impairment, Fluphenazine should generally be avoided. If it must be used, the starting dose should be very low (e.g., 0.5 mg to 1 mg), and liver function tests must be monitored weekly during the titration phase.

> Important: Special populations require individualized medical assessment. Always consult with a specialist if you fall into one of these categories.

Fluphenazine exerts its primary therapeutic effect through the potent antagonism of Dopamine D2 receptors in the mesolimbic and mesocortical tracts of the brain. By binding to these receptors, it inhibits the overactive dopaminergic neurotransmission that characterizes the "positive" symptoms of schizophrenia. Unlike atypical antipsychotics, Fluphenazine has a very high binding affinity for the D2 receptor, often referred to as "tight binding," which explains its high potency and its propensity for causing extrapyramidal symptoms. It also possesses minor blocking activity at Alpha-1 adrenergic, H1 histaminergic, and M1 muscarinic receptors.

The onset of action for oral Fluphenazine Hydrochloride is typically within 1 hour, with peak effects occurring between 2 and 4 hours. The duration of effect for a single oral dose is roughly 6 to 8 hours, though the antipsychotic effect builds over several weeks of consistent dosing. Tolerance to the sedative effects often develops within the first two weeks, but tolerance to the antipsychotic effects does not typically occur.

| Parameter | Value |

|---|---|

| Bioavailability | 40% - 50% (due to first-pass metabolism) |

| Protein Binding | 91% - 99% |

| Half-life | 14 - 24 hours (Oral HCl) |

| Tmax | 1.5 - 2 hours |

| Metabolism | Hepatic (Primary: CYP2D6) |

| Excretion | Renal (approx. 50%), Fecal (approx. 50%) |

• Molecular Formula: C22H26F3N3OS
• Molecular Weight: 437.5 g/mol
• Solubility: Fluphenazine Hydrochloride is soluble in water and alcohol but practically insoluble in benzene and ether.
• Structure: It is a trifluoromethyl phenothiazine derivative with a piperazine side chain. The presence of the trifluoromethyl group increases its potency compared to chlorinated phenothiazines.

Fluphenazine is a member of the Phenothiazine class of antipsychotics. Within this class, it is specifically a piperazine phenothiazine. Other medications in this class include perphenazine and trifluoperazine. It is distinct from the butyrophenone class (e.g., haloperidol) and the thioxanthene class (e.g., thiothixene), although all are considered first-generation antipsychotics.